AIM: To investigate M2 isoform of pyruvate kinase (PKM2) expression in gastric cancers and evaluate its potential as a prognostic biomarker and an anticancer target. METHODS: All tissue samples were derived from gastric cancer patients underwent curative gastrectomy as a primary treatment. Clinical and pathological information were obtained from the medical records. Gene expression microarray data from 60 cancer and 19 non-cancer gastric tissues were analyzed to evaluate the expression level of PKM2 mRNA. Tissue microarrays were constructed from 368 gastric cancer patients. Immunohistochemistry was used to measure PKM2 expression and PKM2 positivity of cancer was determined by proportion of PKM2-positive tumor cells and staining intensity. Association between PKM2 expression and the clinicopathological factors was evaluated and the correlation between PKM2 and cancer prognosis was evaluated. RESULTS: PKM2 mRNA levels were increased more than 2-fold in primary gastric cancers compared to adjacent normal tissues from the same patients (log transformed expression level: 7.6 ± 0.65 vs 6.3 ± 0.51, P < 0.001). Moreover, differentiated type cancers had significantly higher PKM2 mRNA compared to undifferentiated type cancers (log transformed expression level: 7.8 ± 0.70 vs 6.7 ± 0.71, P < 0.001). PKM2 protein was mainly localized in the cytoplasm of primary cancer cells and detected in 144 of 368 (39.1%) human gastric cancer cases. PKM2 expression was not related with stage (P = 0.811), but strongly correlated with gastric cancer differentiation (P < 0.001). Differentiated type cancers expressed more PKM2 protein than did the undifferentiated ones. Well differentiated adenocarcinoma showed 63.6% PKM2-positive cells; in contrast, signet-ring cell cancers showed only 17.7% PKM2-positive cells. Importantly, PKM2 expression was correlated with shorter overall survival (P < 0.05) independent of stage only in signet-ring cell cancers. CONCLUSION: PKM2 expression might be an adverse prognostic factor for signet-ring cell carcinomas. Its function and potential as a prognostic marker should be further verified in gastric cancer.
AIM: To investigate M2 isoform of pyruvate kinase (PKM2) expression in gastric cancers and evaluate its potential as a prognostic biomarker and an anticancer target. METHODS: All tissue samples were derived from gastric cancerpatients underwent curative gastrectomy as a primary treatment. Clinical and pathological information were obtained from the medical records. Gene expression microarray data from 60 cancer and 19 non-cancer gastric tissues were analyzed to evaluate the expression level of PKM2 mRNA. Tissue microarrays were constructed from 368 gastric cancerpatients. Immunohistochemistry was used to measure PKM2 expression and PKM2 positivity of cancer was determined by proportion of PKM2-positive tumor cells and staining intensity. Association between PKM2 expression and the clinicopathological factors was evaluated and the correlation between PKM2 and cancer prognosis was evaluated. RESULTS:PKM2 mRNA levels were increased more than 2-fold in primary gastric cancers compared to adjacent normal tissues from the same patients (log transformed expression level: 7.6 ± 0.65 vs 6.3 ± 0.51, P < 0.001). Moreover, differentiated type cancers had significantly higher PKM2 mRNA compared to undifferentiated type cancers (log transformed expression level: 7.8 ± 0.70 vs 6.7 ± 0.71, P < 0.001). PKM2 protein was mainly localized in the cytoplasm of primary cancer cells and detected in 144 of 368 (39.1%) humangastric cancer cases. PKM2 expression was not related with stage (P = 0.811), but strongly correlated with gastric cancer differentiation (P < 0.001). Differentiated type cancers expressed more PKM2 protein than did the undifferentiated ones. Well differentiated adenocarcinoma showed 63.6% PKM2-positive cells; in contrast, signet-ring cell cancers showed only 17.7% PKM2-positive cells. Importantly, PKM2 expression was correlated with shorter overall survival (P < 0.05) independent of stage only in signet-ring cell cancers. CONCLUSION:PKM2 expression might be an adverse prognostic factor for signet-ring cell carcinomas. Its function and potential as a prognostic marker should be further verified in gastric cancer.
Entities:
Keywords:
Biomarker; Gastric cancer; M2 isoform of pyruvate kinase; Prognosis; Signet ring cell carcinoma
Authors: Dimitrios Anastasiou; George Poulogiannis; John M Asara; Matthew B Boxer; Jian-kang Jiang; Min Shen; Gary Bellinger; Atsuo T Sasaki; Jason W Locasale; Douglas S Auld; Craig J Thomas; Matthew G Vander Heiden; Lewis C Cantley Journal: Science Date: 2011-11-03 Impact factor: 47.728
Authors: H Cerwenka; R Aigner; H Bacher; G Werkgartner; A el-Shabrawi; F Quehenberger; H J Mischinger Journal: Anticancer Res Date: 1999 Jan-Feb Impact factor: 2.480
Authors: Alexander Stahl; Katja Ott; Wolfgang Andreas Weber; Karen Becker; Thomas Link; Jörg-Rüdiger Siewert; Markus Schwaiger; Ulrich Fink Journal: Eur J Nucl Med Mol Imaging Date: 2002-11-08 Impact factor: 9.236
Authors: Su Ting Tay; Siew Hong Leong; Kun Yu; Amit Aggarwal; Soo Yong Tan; Chee How Lee; Keith Wong; Jaya Visvanathan; Dennis Lim; Wai Keong Wong; Khee Chee Soo; Oi Lian Kon; Patrick Tan Journal: Cancer Res Date: 2003-06-15 Impact factor: 12.701
Authors: Xin Chen; Suet Y Leung; Siu T Yuen; Kent-Man Chu; Jiafu Ji; Rui Li; Annie S Y Chan; Simon Law; Olga G Troyanskaya; John Wong; Samuel So; David Botstein; Patrick O Brown Journal: Mol Biol Cell Date: 2003-04-17 Impact factor: 4.138